Search

Displaying results 5171 - 5180 of 5925 in total
  1. Drug

    Pritelivir

    go.drugbank.com/drugs/DB11844
    Investigational

    Pritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.

    Categories: P-glycoprotein substrates
  2. Drug

    Lanicemine

    go.drugbank.com/drugs/DB11889
    Investigational

    Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  3. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the clas...

  6. Drug

    Mafosfamide

    go.drugbank.com/drugs/DB12083
    Investigational

    Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  7. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    PSI-697

    go.drugbank.com/drugs/DB12211
    Investigational

    PSI-697 has been used in trials studying the treatment of Scleritis.

    Categories: P-Selectin
  9. Drug

    Bergapten

    go.drugbank.com/drugs/DB12216
    Investigational

    Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates